미생물학 및 세균 배양 배지 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 용도별, 지역별, 부문별 예측(2026-2033년)

Microbiology & Bacterial Culture Media Market Summary

The global microbiology & bacterial culture media market size was estimated at USD 5.91 billion in 2025 and is projected to reach USD 11.83 billion by 2033, growing at a CAGR of 9.19% from 2026 to 2033. This growth is primarily driven by the rising demand for accurate disease diagnosis, increased research into antimicrobial resistance, and the growing need for microbial testing in food safety & pharmaceutical production.

Advancements in life sciences and biotechnology have expanded the use of culture media in clinical diagnostics, industrial applications, and academic research. Moreover, the surge in infectious disease outbreaks and the expansion of biopharmaceutical manufacturing have amplified the need for specialized and enriched media. These factors, combined with automation in laboratory workflows and increased government funding for microbiological research, fuel market growth globally.

The COVID-19 pandemic has significantly impacted the market. The urgent need for diagnostic testing led to a surge in demand for culture media products suitable for detecting viral infections. This period also saw accelerated technological advancements in microbiology culture, including the development of automated systems and point-of-care testing devices. However, the pandemic disrupted global supply chains, affecting the availability of culture media and associated equipment. Despite these challenges, the role of culture media in vaccine development and research underscores their importance, leading to increased investment and innovation in the sector.

The increasing demand for high-quality culture media in diagnostic applications is another key driver accelerating market growth. Clinical laboratories require precise, reliable, and contamination-free presses to ensure accurate identification and sensitivity testing of microorganisms with the rising global burden of infectious diseases, including bacterial infections, antimicrobial-resistant pathogens, and hospital-acquired infections. Advanced culture media support various diagnostic workflows, from routine bacterial cultures to specialized tests involving fastidious organisms or resistance profiling. As a result, healthcare providers and diagnostic labs prioritize procuring performance-validated, quality-assured media products.

Global Microbiology & Bacterial Culture Media Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global microbiology & bacterial culture media market report based on product, application, and region:

• Product Outlook (Revenue, USD Billion, 2021 - 2033)
• Dehydrated Culture Media
• Ready-to-use Media
• Application Outlook (Revenue, USD Billion, 2021 - 2033)
• Pharmaceutical & Biopharmaceutical Production
• Diagnostics
• Food & Water Testing
  • Food
  • Animal Feed
  • Water Testing
• Bioenergy & Agricultural Research
• Cosmetics and Personal Care Applications
• Others
• Regional Outlook (Revenue, USD Billion, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Western Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Eastern Europe
  • Poland
  • Hungary
  • Czech Republic
  • Bulgaria
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
• Southeast Asia
  • Thailand
  • Vietnam
  • Indonesia
  • Singapore
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • UAE
  • Saudi Arabia
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Application
• 1.3. Research Methodology
• 1.4. Information Procurement
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. List of Secondary Sources
• 1.8. List of Primary Sources
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Microbiology & Bacterial Culture Media Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Growth in global food microbiology testing
    • 3.2.1.2. Rising need for high-quality culture media for diagnostic applications
    • 3.2.1.3. Continuous advancements in biopharmaceutical manufacturing
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High cost of advanced or specialty media
    • 3.2.2.2. Growing preference for alternative methods like molecular diagnostics
• 3.3. Microbiology & bacterial culture media market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTEL Analysis

Chapter 4. Microbiology & Bacterial Culture Media Market: Product Estimates & Trend Analysis

• 4.1. Product Segment Dashboard
• 4.2. Global Microbiology & Bacterial Culture Media Market Product Movement Analysis
• 4.3. Global Microbiology & Bacterial Culture Media Market Size & Trend Analysis, by Product, 2021 - 2033 (USD Million)
• 4.4. Dehydrated Culture Media
  • 4.4.1. Dehydrated Culture Media Market Size & Forecasts and Trend Analysis, 2021 - 2033 (USD Million)
• 4.5. Ready-to-use Media
  • 4.5.1. Ready-to-use Media Market Size & Forecasts and Trend Analysis, 2021 - 2033 (USD Million)

Chapter 5. Microbiology & Bacterial Culture Media Market: Application Estimates & Trend Analysis

• 5.1. Application Segment Dashboard
• 5.2. Global Microbiology & Bacterial Culture Media Market Application Movement Analysis
• 5.3. Global Microbiology & Bacterial Culture Media Market Size & Trend Analysis, by Application, 2021 - 2033 (USD Million)
• 5.4. Pharmaceutical & Biopharmaceutical Production
  • 5.4.1. Pharmaceutical & Biopharmaceutical Production Market Size & Forecasts and Trend Analyses, 2021 - 2033 (USD Million)
• 5.5. Diagnostics
  • 5.5.1. Diagnostics Market Size & Forecasts and Trend Analyses, 2021 - 2033 (USD Million)
• 5.6. Food & Water Testing
  • 5.6.1. Food & Water Testing Market Size & Forecasts and Trend Analyses, 2021 - 2033 (USD Million)
  • 5.6.2. Food
    • 5.6.2.1. Food Market Size & Forecasts and Trend Analyses, 2021 - 2033 (USD Million)
  • 5.6.3. Animal Feed
    • 5.6.3.1. Animal Feed Market Size & Forecasts and Trend Analyses, 2021 - 2033 (USD Million)
  • 5.6.4. Water Testing
    • 5.6.4.1. Water Testing Market Size & Forecasts and Trend Analyses, 2021 - 2033 (USD Million)
• 5.7. Bioenergy & Agricultural Research
  • 5.7.1. Bioenergy & Agricultural Research Market Size & Forecasts and Trend Analyses, 2021 - 2033 (USD Million)
• 5.8. Cosmetics and Personal Care Applications
  • 5.8.1. Cosmetics and Personal Care Applications Market Size & Forecasts and Trend Analyses, 2021 - 2033 (USD Million)
• 5.9. Others
  • 5.9.1. Others Market Size & Forecasts and Trend Analyses, 2021 - 2033 (USD Million)

Chapter 6. Microbiology & Bacterial Culture Media Market: Regional Estimates & Trend Analysis

• 6.1. Regional Market Share Analysis, 2025 & 2033
• 6.2. Regional Market Dashboard
• 6.3. North America
  • 6.3.1. U.S.
    • 6.3.1.1. Key country dynamics
    • 6.3.1.2. Regulatory framework
    • 6.3.1.3. Competitive scenario
    • 6.3.1.4. U.S. market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.3.2. Canada
    • 6.3.2.1. Key country dynamics
    • 6.3.2.2. Regulatory framework
    • 6.3.2.3. Competitive scenario
    • 6.3.2.4. Canada market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.3.3. Mexico
    • 6.3.3.1. Key country dynamics
    • 6.3.3.2. Regulatory framework
    • 6.3.3.3. Competitive scenario
    • 6.3.3.4. Mexico market estimates and forecasts, 2021 - 2033 (USD Million)
• 6.4. Western Europe
  • 6.4.1. UK
    • 6.4.1.1. Key country dynamics
    • 6.4.1.2. Regulatory framework
    • 6.4.1.3. Competitive scenario
    • 6.4.1.4. UK market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.4.2. Germany
    • 6.4.2.1. Key country dynamics
    • 6.4.2.2. Regulatory framework
    • 6.4.2.3. Competitive scenario
    • 6.4.2.4. Germany market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.4.3. France
    • 6.4.3.1. Key country dynamics
    • 6.4.3.2. Regulatory framework
    • 6.4.3.3. Competitive scenario
    • 6.4.3.4. France market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.4.4. Italy
    • 6.4.4.1. Key country dynamics
    • 6.4.4.2. Regulatory framework
    • 6.4.4.3. Competitive scenario
    • 6.4.4.4. Italy market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.4.5. Spain
    • 6.4.5.1. Key country dynamics
    • 6.4.5.2. Regulatory framework
    • 6.4.5.3. Competitive scenario
    • 6.4.5.4. Spain market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.4.6. Norway
    • 6.4.6.1. Key country dynamics
    • 6.4.6.2. Regulatory framework
    • 6.4.6.3. Competitive scenario
    • 6.4.6.4. Norway market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.4.7. Sweden
    • 6.4.7.1. Key country dynamics
    • 6.4.7.2. Regulatory framework
    • 6.4.7.3. Competitive scenario
    • 6.4.7.4. Sweden market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.4.8. Denmark
    • 6.4.8.1. Key country dynamics
    • 6.4.8.2. Regulatory framework
    • 6.4.8.3. Competitive scenario
    • 6.4.8.4. Denmark market estimates and forecasts, 2021 - 2033 (USD Million)
• 6.5. Eastern Europe
  • 6.5.1. Poland
    • 6.5.1.1. Key country dynamics
    • 6.5.1.2. Regulatory framework
    • 6.5.1.3. Competitive scenario
    • 6.5.1.4. Poland market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.5.2. Hungary
    • 6.5.2.1. Key country dynamics
    • 6.5.2.2. Regulatory framework
    • 6.5.2.3. Competitive scenario
    • 6.5.2.4. Hungary market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.5.3. Czech Republic
    • 6.5.3.1. Key country dynamics
    • 6.5.3.2. Regulatory framework
    • 6.5.3.3. Competitive scenario
    • 6.5.3.4. Czech Republic market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.5.4. Bulgaria
    • 6.5.4.1. Key country dynamics
    • 6.5.4.2. Regulatory framework
    • 6.5.4.3. Competitive scenario
    • 6.5.4.4. Bulgaria market estimates and forecasts, 2021 - 2033 (USD Million)
• 6.6. Asia Pacific
  • 6.6.1. Japan
    • 6.6.1.1. Key country dynamics
    • 6.6.1.2. Regulatory framework
    • 6.6.1.3. Competitive scenario
    • 6.6.1.4. Japan market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.6.2. China
    • 6.6.2.1. Key country dynamics
    • 6.6.2.2. Regulatory framework
    • 6.6.2.3. Competitive scenario
    • 6.6.2.4. China market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.6.3. India
    • 6.6.3.1. Key country dynamics
    • 6.6.3.2. Regulatory framework
    • 6.6.3.3. Competitive scenario
    • 6.6.3.4. India market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.6.4. Australia
    • 6.6.4.1. Key country dynamics
    • 6.6.4.2. Regulatory framework
    • 6.6.4.3. Competitive scenario
    • 6.6.4.4. Australia market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.6.5. South Korea
    • 6.6.5.1. Key country dynamics
    • 6.6.5.2. Regulatory framework
    • 6.6.5.3. Competitive scenario
    • 6.6.5.4. South Korea market estimates and forecasts, 2021 - 2033 (USD Million)
• 6.7. Southeast Asia
  • 6.7.1. Thailand
    • 6.7.1.1. Key country dynamics
    • 6.7.1.2. Regulatory framework
    • 6.7.1.3. Competitive scenario
    • 6.7.1.4. Thailand market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.7.2. Vietnam
    • 6.7.2.1. Key country dynamics
    • 6.7.2.2. Regulatory framework
    • 6.7.2.3. Competitive scenario
    • 6.7.2.4. Vietnam market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.7.3. Indonesia
    • 6.7.3.1. Key country dynamics
    • 6.7.3.2. Regulatory framework
    • 6.7.3.3. Competitive scenario
    • 6.7.3.4. Indonesia market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.7.4. Singapore
    • 6.7.4.1. Key country dynamics
    • 6.7.4.2. Regulatory framework
    • 6.7.4.3. Competitive scenario
    • 6.7.4.4. Singapore market estimates and forecasts, 2021 - 2033 (USD Million)
• 6.8. Latin America
  • 6.8.1. Brazil
    • 6.8.1.1. Key country dynamics
    • 6.8.1.2. Regulatory framework
    • 6.8.1.3. Competitive scenario
    • 6.8.1.4. Brazil market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.8.2. Argentina
    • 6.8.2.1. Key country dynamics
    • 6.8.2.2. Regulatory framework
    • 6.8.2.3. Competitive scenario
    • 6.8.2.4. Argentina market estimates and forecasts, 2021 - 2033 (USD Million)
• 6.9. MEA
  • 6.9.1. South Africa
    • 6.9.1.1. Key country dynamics
    • 6.9.1.2. Regulatory framework
    • 6.9.1.3. Competitive scenario
    • 6.9.1.4. South Africa market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.9.2. Saudi Arabia
    • 6.9.2.1. Key country dynamics
    • 6.9.2.2. Regulatory framework
    • 6.9.2.3. Competitive scenario
    • 6.9.2.4. Saudi Arabia market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.9.3. UAE
    • 6.9.3.1. Key country dynamics
    • 6.9.3.2. Regulatory framework
    • 6.9.3.3. Competitive scenario
    • 6.9.3.4. UAE market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.9.4. Kuwait
    • 6.9.4.1. Key country dynamics
    • 6.9.4.2. Regulatory framework
    • 6.9.4.3. Competitive scenario
    • 6.9.4.4. Kuwait market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Company/Competition Categorization
• 7.2. Strategy Mapping
• 7.3. Company Market Position Analysis, 2025
• 7.4. Company Profiles/Listing
  • 7.4.1. Merck KGaA
    • 7.4.1.1. Company overview
    • 7.4.1.2. Financial performance
    • 7.4.1.3. Product benchmarking
    • 7.4.1.4. Strategic initiatives
  • 7.4.2. bioMerieux SA
    • 7.4.2.1. Company overview
    • 7.4.2.2. Financial performance
    • 7.4.2.3. Product benchmarking
    • 7.4.2.4. Strategic initiatives
  • 7.4.3. HiMedia Laboratories
    • 7.4.3.1. Company overview
    • 7.4.3.2. Financial performance
    • 7.4.3.3. Product benchmarking
    • 7.4.3.4. Strategic initiatives
  • 7.4.4. Thermo Fisher Scientific Inc.
    • 7.4.4.1. Company overview
    • 7.4.4.2. Financial performance
    • 7.4.4.3. Product benchmarking
    • 7.4.4.4. Strategic initiatives
  • 7.4.5. BD
    • 7.4.5.1. Company overview
    • 7.4.5.2. Financial performance
    • 7.4.5.3. Product benchmarking
    • 7.4.5.4. Strategic initiatives
  • 7.4.6. Solabia Group (Biokar diagnostics)
    • 7.4.6.1. Company overview
    • 7.4.6.2. Financial performance
    • 7.4.6.3. Product benchmarking
    • 7.4.6.4. Strategic initiatives
  • 7.4.7. Titan Biotech Ltd.
    • 7.4.7.1. Company overview
    • 7.4.7.2. Financial performance
    • 7.4.7.3. Product benchmarking
    • 7.4.7.4. Strategic initiatives
  • 7.4.8. CONDALAB
    • 7.4.8.1. Company overview
    • 7.4.8.2. Financial performance
    • 7.4.8.3. Product benchmarking
    • 7.4.8.4. Strategic initiatives
  • 7.4.9. Neogen Corporation
    • 7.4.9.1. Company overview
    • 7.4.9.2. Financial performance
    • 7.4.9.3. Product benchmarking
    • 7.4.9.4. Strategic initiatives
  • 7.4.10. Bio-Rad Laboratories, Inc.
    • 7.4.10.1. Company overview
    • 7.4.10.2. Financial performance
    • 7.4.10.3. Product benchmarking
    • 7.4.10.4. Strategic initiatives
  • 7.4.11. SHIMADZU
    • 7.4.11.1. Company overview
    • 7.4.11.2. Financial performance
    • 7.4.11.3. Product benchmarking
    • 7.4.11.4. Strategic initiatives
  • 7.4.12. Hardy Diagnostics
    • 7.4.12.1. Company overview
    • 7.4.12.2. Financial performance
    • 7.4.12.3. Product benchmarking
    • 7.4.12.4. Strategic initiatives
  • 7.4.13. R-Biopharm AG
    • 7.4.13.1. Company overview
    • 7.4.13.2. Financial performance
    • 7.4.13.3. Product benchmarking
    • 7.4.13.4. Strategic initiatives
  • 7.4.14. Alpha Teknova, Inc.
    • 7.4.14.1. Company overview
    • 7.4.14.2. Financial performance
    • 7.4.14.3. Product benchmarking
    • 7.4.14.4. Strategic initiatives
  • 7.4.15. MP Biomedicals
    • 7.4.15.1. Company overview
    • 7.4.15.2. Financial performance
    • 7.4.15.3. Product benchmarking
    • 7.4.15.4. Strategic initiatives
  • 7.4.16. Micromaster Laboratories Pvt. Ltd.
    • 7.4.16.1. Company overview
    • 7.4.16.2. Financial performance
    • 7.4.16.3. Product benchmarking
    • 7.4.16.4. Strategic initiatives
  • 7.4.17. ELEX Biological Products (Shanghai) Co., Ltd.
    • 7.4.17.1. Company overview
    • 7.4.17.2. Financial performance
    • 7.4.17.3. Product benchmarking
    • 7.4.17.4. Strategic initiatives
  • 7.4.18. Eiken Chemical Co., Ltd.
    • 7.4.18.1. Company overview
    • 7.4.18.2. Financial performance
    • 7.4.18.3. Product benchmarking
    • 7.4.18.4. Strategic initiatives